What is circulating tumor cells?
Circulating tumor cells are the lurking
foes shed from primary tumor mess into a cancer patient's circulation systems,
including blood and lymphatic systems. circulating tumor cells (CTCs) are
rare. How rare? In a metastatic cancer patient, typically it’s only 1 CTC per
billions of red blood cells, or a single digit per 10 ml of blood. However, the
rare CTCs act like dangerous seeds, lurking in the circulation and seeking new
sites to lodge and grow. The tumor transfer to remote organs is called
metastasis.
Shocking Facts
Metastatic
carcinoma is the main cause of death in cancer patients. And the metastases are
taking place via circulating tumor cells. In advanced colorectal cancer,
patients with a CTC count >3 per 7.5ml blood had a worse therapeutic outcome
[1]. In breast cancer, patients had CTC count of >5 per 7.5ml blood had
significant shorter median survival (6.7 months) and overall survival (13.2
months). A study published in New England Journal of Medicine even revealed
that the progression-free survival is only 2.7 months for patients who had CTC
count >5 [2].
A Little More to Know
The only FDA approved CTC counting method
is CellSearch (
https://www.cellsearchctc.com/)
CTC test. CellSearch system use magnetic beads coated with anti-EpCAM
antibodies to target CTCS for enrichment and with immune-fluorescence labeling
for identifying and counting. There is no approved method or drug to
specifically kill CTCs inside human body.
The CELLSEARCH® System is the result
of a commitment to innovation that began in 1999 and led to the first
standardized, FDA-cleared, semi-automatic system that can capture and quantify
circulating tumor cells from a 7.5-mL blood sample with a high level of
sensitivity and specificity (adapted from CELLSEARCH website).
Current research work focuses on
capturing, enumerating, and characterizing CTCs in blood samples [4]. The
most commonly way to capture CTCs relies on the antibody that binds to surface
protein. Through immune-labeling with either magnetic or fluorescence tags,
CTCs can be isolated for imaging and analysis to recognize its molecular signature.
CTCs are seeding cells originated from primary tumor mass. Current
research efforts on CTCs focus on methods of capturing, isolating, and
identifying the cells for the purpose of diagnosis and characterization of
phenotype signature. Lodging of the rare lurking foes results in the metastases
of a tumor to remote organs and leads to fatal consequences. However, it’s
still very hard to effectively find and capture the dangerous seeds. The figure
shows a brief of recent research work [3].
Citations
[1] J Clin
Oncol 26:3213-3221, 2008
[2] N Engl J
Med 351; 8 781-791, 2004
[3] Science
Vol.327, 26 Feb., 2010
[4] D. R.
Parkinson et al., Considerations in the development of circulating tumor cell
technology for clinical use. J Translational Medicin 10:138, 2012.